D-0514-2026 Class II Ongoing
FDA drug recall D-0514-2026 was initiated by Ajanta Pharma Ltd. on Apr 29, 2026 and is designated Class II. Reason for recall: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals. The recall status is ongoing. Affected quantity: 312,894 packs.
Recall details
- Product Type
- Drugs
- Report Date
- May 13, 2026
- Initiation Date
- Apr 29, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 312,894 packs
Product description
Duloxetine Delayed-Release Capsules, 30 mg, Rx Only, a) 90 Capsules, NDC 27241-098-09, b) 30 capsules, NDC 27241-098-03, c) 1000 Capsules, NDC 27241-098-10, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India
Reason for recall
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.
Distribution pattern
Nationwide within U.S
Code information
Lot#: a) PA10774, Exp. May 2026; b) PA10794, PA12174, Exp. Jun 2026; c) PA10804, Exp. Jun-26.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0514-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026